Materias dentro de su búsqueda.
Mostrando 4,521 - 4,540 Resultados de 4,918 Para Buscar '"Pfizer"', tiempo de consulta: 0.35s Limitar resultados
  1. 4521
    “…Cleveland, MD, AbbVie: Honoraria|Cumberland: Honoraria|Merck: Honoraria|Pfizer: Honoraria Pedro L. Gonzalez, MD, MT, AbbVie: Employee of AbbVie at the time of study conduct and analysis.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1660. Dalbavancin Utilization Registry Investigating Value and Effectiveness (DRIVE): Outcomes Report on Real-World Use
  2. 4522
    “…Kaplan, MD, MeMed: Grant/Research Support|Pfizer: Grant/Research Support Jonathon C. McNeil, MD, Agency for Healthcare Research and Quality: Grant/Research Support|Allergan: Provided reagents for unrelated research|Nabriva: Site investigator for multicenter clinical trial Cesar A. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1543. Validation of a Nitrocefin-based Rapid Test for the Detection of the Cefazolin Inoculum Effect in Pediatric Patients with Methicillin-Susceptible Staphylococcus aureus Acute Osteomyelitis
  3. 4523
    “…Lee, PhD, MPH, CDC: Grant/Research Support|Merck: Grant/Research Support Christopher J Harrison, MD, Astellas: Grant/Research Support|GSK: Grant/Research Support|Merck: Grant/Research Support|Pediatric news: Honoraria|Pfizer: Grant/Research Support Rangaraj Selvarangan, BVSc, PhD, D(ABMM), FIDSA, F(AAM), BioFire: Grant/Research Support|Luminex: Grant/Research Support.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    495. Enterovirus Genotype Specific Immune Response in Cerebrospinal Fluid of Infected Infants
  4. 4524
    “…DISCLOSURES: Hanna-Riikka Kreivi, MD, PhD, Pfizer: Advisor/Consultant|Roche: Advisor/Consultant Tuomas Rosberg, MD, PhD, AstraZeneca: Honoraria|Boehringer-Ingelheim: Honoraria|GSK: Honoraria.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1126. Effect of Remdesivir on Recovery, Quality of Life, and Long-COVID Symptoms One Year after Hospitalization for COVID-19 Infection: A Randomized Controlled SOLIDARITY Finland Trial
  5. 4525
    “…BACKGROUND: Synthesising evidence on the long-term vaccine effectiveness of COVID-19 vaccines (BNT162b2 [Pfizer–BioNTech], mRNA-1273 [Moderna], ChAdOx1 nCoV-19 [AZD1222; Oxford–AstraZeneca], and Ad26.COV2.S [Janssen]) against infections, hospitalisations, and mortality is crucial to making evidence-based pandemic policy decisions. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022
  6. 4526
    “…The odds of SEs were higher with Moderna Spikevax, AstraZeneca/Oxford and Johnson and Johnson vaccines than after the Pfizer vaccine (p< 0.0001). The overall rate of AEs post-vaccine was similar between patients with CeD and non-CeD individuals (aOR= 1.29; 95% CI= 0.89-1.87). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A13 THE RATE OF ADVERSE EVENTS AFTER COVID-19 VACCINATION IS SIMILAR IN PATIENTS WITH CELIAC DISEASE AND NON-CELIAC POPULATION: RESULTS OF A LARGE INTERNATIONAL CROSS-SECTIONAL STUDY
  7. 4527
    “…Wilson Consultant of: Consulting fees from Fresenius Kabi, Speakers bureau of: Speaking fees from Takeda and Pfizer…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A174 A NOVEL MECHANISM OF CROHN’S DISEASE SEVERITY IN WOMEN: EVALUATING THE IMPACT OF AN ESTROGEN-FARNESOID X RECEPTOR INTERACTION ON INTESTINAL BARRIER FUNCTION
  8. 4528
    por Toure, H. Attoh, Oussou, K., Agoh, F.
    Publicado 2023
    “…Parmi les personnes vaccinés, 66,1 % avait reçu deux doses de vaccin et le vaccin de Pfizer-BioNtech était le plus utilisé (55,7 %). Les principales raisons de l'hésitation vaccinale étaient la peur des effets secondaires, l'inefficacité du vaccin, les rumeurs et le déni de la maladie. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    P059 - Acceptabilité de la vaccination contre la COVID-19 par les usagers de deux structures de santé dans la commune de Yopougon en Côte d'Ivoire
  9. 4529
    “…FUNDING: Ivermectin (Mectizan) was donated by the Mectizan Donation Program, albendazole was donated by GlaxoSmithKline, and azithromycin (Zithromax®) was donated by Pfizer via the International Trachoma Initiative (ITI). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety of integrated mass drug administration of azithromycin, albendazole and ivermectin versus standard treatment regimens: a cluster-randomised trial in Ethiopia
  10. 4530
    “…Blood samples of pwMS with or without DMTs and healthy controls were collected after two doses of inactivated virus (Sinovac) or mRNA (Pfizer-BioNTech) vaccines. PwMS were sub-grouped according to the mode of action of the DMTs that they were receiving. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity—Does it matter?
  11. 4531
    “…Main funding source(s): Pfizer BACKGROUND: Type 1 long QT syndrome (LQT1) is a genetic channelopathy characterized by both haploinsufficient and dominant-negative loss-of-function pathogenic variants in the KCNQ1-encoded Kv7.1 K+ channels conducting IKs. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    In vivo KCNQ1-suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome
  12. 4532
    “…Main funding source(s): Bristol Myers Squibb and Pfizer. BACKGROUND: Undiagnosed atrial fibrillation (AF) is associated with a higher risk of stroke and mortality. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Identification of a real-world clinical model associated with atrial fibrillation in a large french primary care database
  13. 4533
    “…METHODS: Uninfected subjects who received 3 doses of mRNA vaccines (BNT162b2 [Pfizer-BioNTech, BNT] and mRNA-1273 [Moderna]), viral vector-based vaccines (ChAdOx1-S (AZD1222, AZ) or protein subunit vaccines (Medigen COVID-19 vaccine) were prospectively enrolled. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort
  14. 4534
    “…RESULTS: In total, 356 students participated, of whom 219 (61.5%) had received a primary vaccine series of Pfizer-BioNTech or Moderna mRNA vaccines and 85 (23.9%) had received vaccines from Sinovac or Sinopharm. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Assessment of Anti-SARS-CoV-2 antibody levels among university students vaccinated with different COVID-19 primary and booster doses — fall 2021, Wisconsin
  15. 4535
    “…We included individuals (aged ≥16 years) a mean of 35 days (range 27–43) after they had received a second dose of the BNT162b2 (Pfizer–BioNTech) COVID-19 vaccine. We quantified associations between immunological parameters and breakthrough infection and assessed whether information on these parameters improves risk discrimination. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial
  16. 4536
    por Doskaliuk, Bohdana, Ravichandran, Naveen, Sen, Parikshit, Day, Jessica, Joshi, Mrudula, Nune, Arvind, Nikiphorou, Elena, Saha, Sreoshy, Tan, Ai Lyn, Shinjo, Samuel Katsuyuki, Ziade, Nelly, Velikova, Tsvetelina, Milchert, Marcin, Jagtap, Kshitij, Parodis, Ioannis, Gracia-Ramos, Abraham Edgar, Cavagna, Lorenzo, Kuwana, Masataka, Knitza, Johannes, Chen, Yi Ming, Makol, Ashima, Agarwal, Vishwesh, Patel, Aarat, Pauling, John D., Wincup, Chris, Barman, Bhupen, Tehozol, Erick Adrian Zamora, Serrano, Jorge Rojas, La Torre, Ignacio García-De, Colunga-Pedraza, Iris J., Merayo-Chalico, Javier, Chibuzo, Okwara Celestine, Katchamart, Wanruchada, Goo, Phonpen Akarawatcharangura, Shumnalieva, Russka, Hoff, Leonardo Santos, Kibbi, Lina El, Halabi, Hussein, Vaidya, Binit, Shaharir, Syahrul Sazliyana, Hasan, A. T. M. Tanveer, Dey, Dzifa, Gutiérrez, Carlos Enrique Toro, Caballero-Uribe, Carlo V., Lilleker, James B., Salim, Babur, Gheita, Tamer, Chatterjee, Tulika, Distler, Oliver, Saavedra, Miguel A., Chinoy, Hector, Agarwal, Vikas, Aggarwal, Rohit, Gupta, Latika
    Publicado 2023
    “…IIM patients with active disease, overlap myositis, autoimmune comorbidities, and ChadOx1 nCOV-19 (Oxford/AstraZeneca) recipients reported AEs more often, while those with inclusion body myositis, and BNT162b2 (Pfizer) recipients reported fewer AEs. Vaccination is reassuringly safe in individuals with IIMs, with AEs, hospitalizations comparable to SAIDs, and largely limited to those with autoimmune multimorbidity and active disease. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study
  17. 4537
    “…Pregnant individuals receiving COVID-19 mRNA vaccines (mRNA-1273 [Moderna] and BNT162b2 [Pfizer-BioNTech]) were eligible. Of 81 participants enrolled, 5 were excluded after enrollment: 1 terminated pregnancy, 1 received the third vaccine dose prior to delivery, and 3 delivered prior to completing the initial vaccine series. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Assessment of Adverse Reactions, Antibody Patterns, and 12-month Outcomes in the Mother-Infant Dyad After COVID-19 mRNA Vaccination in Pregnancy
  18. 4538
    “…PARTICIPANTS: All adults aged ≥18 years who had received at least a primary vaccination schedule of AZD1222 (Oxford-AstraZeneca) or monovalent SARS-CoV-2 wild type (ancestral) strain based mRNA vaccines BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna), in any combination. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses
  19. 4539
    “…MAIN OUTCOME MEASURES: The Kaplan-Meier estimator was used to compare the risk of hospital admission and death related to covid-19 in people who received a bivalent Comirnaty (Pfizer-BioNTech) or Spikevax (Moderna) BA.4-5 or BA.1 mRNA booster vaccine as a fourth dose (second booster) with three dose (first booster) vaccinated people and between four dose vaccinated people. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study
  20. 4540
    “…Due to comparably low severity of omicron variant and high vaccine coverage (~80% residents fully vaccinated with AstraZeneca, Moderna, or Pfizer BioNTech COVID-19 vaccines as of March 2022), the policy was shifted from containment to co-existing with COVID-19 in Taiwan. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    To PCR or not? The impact of shifting policy from PCR to rapid antigen tests to diagnose COVID-19 during the omicron epidemic: a nationwide surveillance study
Herramientas de búsqueda: RSS